Hypomethylating Agents Market, by Agent Type (Decitabine, Azacitidine), Treatment (Acute Myeloid, Leukemia, Myelodysplastic Syndromes), Gender (Male, Female), Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2019–2026

Global Hypomethylating Agents Market Overview 2026:

DNA methylation is a type of biological process by which methyl group is added to the DNA molecule. Hypomethylating agents are drugs that hinder DNA methylation. Hypomethylating agents are crucial medicines for the treatment of health disorders including acute myeloid leukemia (AML) and myelodysplastic syndrome. Hypomethylating agents are used in epigenetic therapy, which is the usage of drugs or chemicals epigenome to influence techniques for the treatment of several diseases such as heart disease, mental illness, diabetes and cancer.

Increase in the aged population and increasing awareness about the use of hypomethylating agents are significantly driving the growth of the Hypomethylating Agents Market 

Growing myelodysplastic syndrome (MDS) disease cases across the globe within aged population, growing awareness of hypomethylating agents such as decitabine, and the importance of azacytidine in chemotherapy are the key Hypomethylating Agents Market drivers. In aged people, health disorders are most common problems and health problems progressively rise with growing age. The occurrence of MDS disease in the aged population is high, which is expected to drive the market size in the estimated time. As per the study conducted by American Cancer Society (ACS), around 10,000 new cases are diagnosed with cancer every year in the U.S, and the number of cases is predicted to grow day by day. This factor will drive the demand for hypomethylating agents (these agents are chemotherapy drugs). Furthermore, growing initiatives taken by the governments to provide specific treatments along with increasing funds for healthcare advancements are projected to impel the growth of the market.

Continuous growth in the developments of hypomethylating agents are projected to generate major investment opportunities in the hypomethylating agents market

Constant increase in the advancements in hypomethylating agents for better understanding of the agent’s mechanism and improvements in the myelodysplastic syndrome to reduce the complexity of the treatment by developing the novel treatment methods are anticipated to create significant growth opportunities in the Hypomethylating Agents Market. Moreover, researchers are focusing on the novel combinations of hypomethylating agents for advanced myelodysplastic syndrome and acute myeloid leukemia for older adults and improving the treatment response; these factors are anticipated to propel the Hypomethylating Agents Market growth in the coming years.

Decitabine and azacitidine agents will witness to grow at a significant rate during the estimated time

Decitabine and azacitidine are anti-cancer chemotherapy medicines and hymethylating agents. Decitabine agents are used for myelodysplastic syndrome treatment and azacitidine agents are used for myelodysplastic syndrome treatment and chronic myelomonocytic leukemia. These agents have exhibited improved results for the myelodysplastic syndrome and the response rate of decitabine agents is around 70%, which is higher than the response rate of azacytidine agents. Decitabine agent type is expected to dominate the market size and projected to grow with substantial growth during the forecast period. Also, the market for Azacitidine agent type is projected to experience healthy growth during the projected time.

Myelodysplastic Syndrome was registered for largest market share and is projected to grow at a faster rate during the estimated time

Myelodysplastic syndrome (MDS) accounted for the highest Hypomethylating Agents Market size in 2018 and is projected to continue its growth in the estimated period. Myelodysplastic syndrome is a group of disorders caused by unwell blood cells or immature blood cells and results something wrong in the bones such as bone marrow. Myelodysplastic syndromes are caused due to exposure to the specific chemicals include tobacco smoke, benzene and other chemicals and heavy metals include lead, cadmium, arsenic, mercury and other heavy metals.  These factors are projected to drive the growth of the market in the estimated period. Also, increasing the developments in the treatment of myelodysplastic syndrome is anticipated to drive the market size in the coming years. Acute myeloid leukemia treatment (AML) will witness to grow at a healthy rate during the forecast period. This expected growth is because of increasing number of tobacco smokers and the number of patients suffering from blood disorders.

Male gender segment is accounted for the highest market size and is anticipated to continue its growth in the projected time

Male population accounted for the largest hypomethylating agents market size and is projected to continue its increase in the market size during the estimated time. This growth is mainly because incidence of cancer is more common in men than women. For instance, as per American Cancer Society (ACS), in 2019, around 61,780 new cancer cases of leukemia have been diagnosed in the U.S. and out of these new cases, around 22,840 deaths are estimated; in these, 13,150 deaths are especially men. This factor is projected to drive the market growth in the forecast time. The increase in the prevalence of cancer among women is projected to increase the market size for the female segment.

Asia-Pacific market is projected to have major investment opportunities for the investors to grow in the coming years

The global hypomethylating agents market was dominated by North America region and is projected to experience significant growth and is estimated to account for prime market share during the forecast period. This dominance is attributed to the presence of improved healthcare infrastructure and increase in the treatment amenities in the North America region. The U.S accounted for the major market share in the North America region, due to existence of major pharmaceutical manufacturers. In addition, existence of key research and development establishments such as Acute Coronary Syndrome (ACS), UC San Diego Health Sciences (UCSD Health Sciences), National Institutes of Health (NIH) and other organizations are anticipated to enhance the market size in the forecast time.
Asia-Pacific region is anticipated to grow at a noteworthy rate and is expected to produce significant revenue growth opportunities in the forecast period. This growth is majorly owing to increase in the number of pharmaceutical companies across the Asia-Pacific region. In addition, many manufacturers are concentrating on the development of the hypomethylatic agents and there is an increase in the number of patients suffering from MDS and AML disorders. Also, increasing investments on healthcare infrastructure are increasing the demand for hypomethylating agents and growing the awareness on hematologic malignancy disorders; these aspects will drive the growth of the market in the projected period.
To explore more about hypomethylating agents market, get in touch with our analysts here.https://www.researchdive.com/connect-to-analyst/113

Product launches and mergers & acquisitions are the major strategies followed by the key players

Source: Research Dive Analysis

BP Pharmaceuticals, Laboratories Company, Dr. Reddy’s Laboratories Ltd, Cipla Inc., Astex Pharmaceuticals, Takeda Pharmaceutical Company Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd, CELGENE CORPORATION, Otsuka Holdings Co., Ltd. and Amgen Inc. are the major hypomethylating agents market players. These major players are increasing their efforts to improve the product quality & performance, R&D activities, new product launches, product developments, mergers & acquisitions and joint ventures to gain majority of the market share in the overall hypomethylating agent’s industry.
 

Source: Research Dive Analysis